Ripptide Pharma has developed a chemoenzymatic process for the efficient production of macrocycles and cyclic peptides, addressing entirely novel areas of chemical space for drug discovery and development.
Macrocycles are new therapeutics in areas only currently accessible through biologics, such as protein-protein interactions. Unlike biologics they can be administered orally and access therapeutic targets within the cell.
Our technology is available to partners to discover or optimise macrocycles in their areas of therapeutic interest
Ripptide is advancing its in-house drug discovery/development activities in unmet areas of inflammation, autoimmune disease and cancer.
To discuss access to Ripptide’s technology contact Dr Bill Primrose, CEO
Tel: +44 (0)1223 247468